Ana Vivancos
Has grant
Principal Investigator
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
CeLac and European consortium for a personalized medicine approach to Gastric Cancer-LEGACy
Open Date: 2019-01-01
Close Date: 2022-12-01
Grant: Close
Tumores primarios múltiples en pacientes con cáncer de pulmón: elaboración de un perfil molecular integral para elucidar orígenes genéticos comunes
Open Date: 2019-01-01
Close Date: 2023-01-01
Grant: Close
Measuring NRG1 mRNA levels by means of Nanostring at Vall d'Hebron
Open Date: 2019-01-01
Close Date: 2020-01-01
Grant: Close
Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GECJ)
Open Date: 2019-01-01
Close Date: 2026-01-01
Grant: Close
Biomarker testing NSG analysis
Open Date: 2019-01-01
Close Date: 2020-01-01
Articles (16)
Purpose: Gene fusions are molecular rearrangements with oncogenic potential. However, their role in disease progression and therapy resistance remains largely unexplored, particularly in breast cancer. Experimental Design: In this study, we utilized multiomics data from the AURORA program to characterize gene fusions in metastatic breast cancer. We analyzed RNA sequencing data from 325 primary tumors and 350 metastatic lesions across 476 patients to develop a high-confidence catalog of gene fusions. Results: In a subset of 398 matched samples from 199 patients, we observed a higher burden of gene fusions in metastatic tumors compared with their corresponding primary tumors. Metastatic-specific (acquired) gene fusions were characterized by few recurrent rearrangements and were generally absent in patients with de novo metastatic disease. We observed a colocalization of gene fusions with subtype-specific copy-number gains. Various scores indicative of genomic instability were found to be associated with the gene fusion burden. Fusions involving genes located within the same topologically associating domain (TAD) were common in HER2-positive tumors and frequently acquired in metastatic triple-negative breast cancer. The presence of gene fusions, particularly those that were acquired or involved in genes within the same TAD, was associated with poor prognosis in estrogen receptor–positive/HER2-negative tumors. Patients with acquired ESR1 fusions exhibited a more aggressive disease course, characterized by shorter treatment response and poorer clinical outcomes. Conclusions: The AURORA gene fusion catalog may serve as a valuable resource for identifying targetable genetic alterations, thereby supporting the development of more effective therapeutic strategies for breast cancer.
Year:
2026
Evaluation of RAD51 scores in CCA_PDXs and CCA patients. (A) RAD51 scores of CCA_PDXs and their matched originating biopsy samples. (B) RAD51 scores evaluated in PDX85 (IDH1mut) treated as for Figure 4C.
Year:
2025
Growth of cells derived from CCA_PDXs in the 3D ex vivo culture system. (A) Representative bright-field images of cells derived from indicated CCA_PDXs and cultured ex vivo. Images are from days 0, 3, 7, and 10. Scale bar, 1 mm.
Year:
2025
Histopathologic characterization of CCA_PDXs. (A) Histologic and immunohistochemical images of CCA_PDXs. H&E staining, and immunohistochemical staining of KRT19 (CCA marker) and HepPar1 (HCC marker) were shown. CCA_PDX samples were collected at passage 1 (PDX41, PDX96, PDX118, PDX123, PDX132, and PDX133) or passage 2 (PDX58, PDX62, PDX67, PDX68.2, PDX75, PDX75.2, PDX78, PDX84, PDX85, PDX104, PDX119, and PDX120). Scale bar, 250 µm.
Year:
2025
Absence of PARP inhibitor efficacy in IDH1mut, ARID1Amut, or BAP1mut CCA_PDXs. (A) Dose-response curves of niraparib for a panel of tumoroids derived from CCA_PDXs. Cell viability was determined using Cell Titer-Glo assay 7 days after the treatment initiation. Data are mean ± s.d. from independent biological replicates. PDX41, n=3; PDX78, n=3; PDX85, n=6; PDX75, n=2; PDX75.2, n=2; PDX118, n=3; PDX133, n=3. (B) Half-maximal inhibitory concentration (IC50) of niraparib in tumoroids derived from CCA_PDXs. (C) Representative images of immunohistochemical staining for a cell proliferation marker (Ki67) and apoptosis marker cleaved caspase 3 in PDX85 cells treated as for Fig 4C. (D) Representative images of immunohistochemical staining for cell proliferation marker (Ki67) and apoptosis marker cleaved caspase 3 in PDX78 treated as for Fig 4D. Scale bar, 250 µm.
Year:
2025
Genomic rearrangements resulting in FGFR2 fusions. (A) Genomic rearrangements resulting in FGFR2 fusion identified in CCA_PDX and the corresponding biopsy samples. Fusion partner genes, their accession number, breakpoints, and predicted chimeric protein products are indicated.
Year:
2025
Tissue biomarker analyses and the VIGex score. A, Immune tumor contexture of the basal samples and surgical specimens in patients with MPR ( n = 8) and without MPR ( n = 25). B, Gene expression profile on surgical specimens, integrated within the VIGex score, and individual gene expression profile on surgical specimens. CK, cytokeratin; Post-ttm, posttreatment.
Year:
2025
Purpose: Immune checkpoint inhibitors combined with chemotherapy have provided successful results in patients with gastric and gastroesophageal junction (G/GEJ) cancers in the metastatic setting. Similar strategies have been explored in earlier stages. In this study, we present the final results of the phase II MONEO trial, which evaluated the addition of avelumab to neoadjuvant chemotherapy. Patients and Methods: Patients with untreated, resectable G/GEJ adenocarcinoma received neoadjuvant treatment with four cycles of avelumab plus the FLOT4 regimen, followed by surgery. Upon postoperative recovery, patients underwent four additional adjuvant cycles of the same combination, followed by avelumab monotherapy for up to 1 year. The primary endpoint was pathologic complete response rate. Sequential flow cytometry and cytokine determination were performed in peripheral blood, along with multiplex tissue immunofluorescence and RNA sequencing in tumor specimens. Results: Forty patients were enrolled, achieving a pathologic complete response rate of 21.1% (95% confidence interval, 10.0–37.0). The major pathologic response rate was 28.9%, more pronounced in patients with tumors expressing PD-L1 before treatment as measured by the combined positive score (cutoff, 10; 33.3% vs. 21.1%). The results propose several potential biomarkers considering tumor immune infiltrate, circulating immune cells, and cytokines. Eighty percent of patients experienced treatment-related grade ≥3 adverse events. Conclusions: The combination of avelumab plus the FLOT4 regimen showed relatively modest efficacy in resectable G/GEJ adenocarcinoma. Better results were observed in PD-L1 combined positive score ≥10% tumors. Exploratory biomarker analyses provide insights that may help to identify candidates most likely to benefit from chemoimmunotherapy as a neoadjuvant treatment.
Year:
2025
Analyses on circulating cytokines and leukocytes. A, Mean difference in peripheral cytokines (fold change) at cycle 1, cycle 2, and at presurgery evaluation between patients with MPR ( n = 11) and without MPR ( n = 25). B, Peripheral immune cells quantified as percentages and compared baseline and posttreatment results showing the difference between pCR ( n = 3) and non-pCR ( n = 8) patients, with the delta in patients with pCR as indicated. Positive (green) or negative (red) differences are color-coded, and the magnitude is reflected by the intensity of the color. MDSC, myeloid-derived suppressor cell; PBM, peripheral blood mononuclear; PMN, polymorphonuclear; TR/EG, regulatory T cells.
Year:
2025
Efficacy endpoints. A, Percentage of tumor regression grade. B, Tumor regression grade depending on PD-L1 CPS, HER2, and MMR status. C, PFS. D, OS. E, Subgroup analysis for PFS. F, Subgroup analysis for OS. pMMR, MMR-proficient.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (50)
Maria Carmen Ochoa
Associate researcher
Center for Applied Medical Research
Aaron R. Hansen
Medical Oncologist
University Health Network
Mariano Ponz-Sarvise
Universidad de Navarra
SONIA PERNAS SIMON
Associate Professor
University of Barcelona
Christos Sotiriou
Université libre de Bruxelles
Alena Gros
Group Leader
Vall d'Hebron Institute of Oncology
Aleix Prat
Director Clínic Barcelona Comprehensive Cancer Centre (4C)
Hospital Clínic de Barcelona
Albiruni R. Abdul Razak
University Health Network
Daniel Álvarez de la Sierra
Vall d'Hebron Research Institute
Peter Katsikis
Professor & Head
Erasmus University Medical Center
Anthony Turpin
Centre Hospitalier Régional Universitaire de Lille
Matteo Benelli
Head of Bioinformatics Unit
Azienda Usl Toscana Centro
Andrea Vingiani
Fondazione IRCCS Istituto Nazionale dei Tumori
Raquel Perez-Lopez
Vall d'Hebron Institut de Recerca
Joaquin Arribas
Research Director
Hospital del Mar
Pamela S. Ohashi
University of Toronto
ENRIQUE JAVIER ARENAS LAHUERTA
Institute for Research in Biomedicine
Jose A Seoane
Junior Group Leader
Vall d'Hebron Institute of Oncology
Hector Palmer
Director
Vall d'Hebron Institute of Oncology
Winona Oliveros
KTH Royal Institute of Technology
Ignacio Melero
Kidani Professor of Cancer Immuno-Therapeutics
University of Oxford
Cindy Neuzillet
PU PH
Université de Versailles Saint-Quentin-en-Yvelines
Josep Tabernero
Associate Professor Faculty of Medicine
Universitat de Vic - Universitat Central de Catalunya
Philippe L. Bedard
University Health Network
Giuseppe Curigliano
European Institute of Oncology
Elisa Agostinetto
Institut Jules Bordet
Marta Mele
Group leader
Barcelona Supercomputing Center
Oscar Pozo
Miguel Servet II
Institut Hospital del Mar d'Investigacions Mèdiques
Roger Colobran
Head of Translational Immunology Research Group
Vall d'Hebron Institut de Recerca
Ricardo Pujol Borrell
Universitat Autònoma de Barcelona (UAB)
Elena Garralda
Director
-
Mónica Martínez Gallo
Principal Researcher
Vall d'Hebron Institut de Recerca
Guillermo Villacampa Javierre
Biostatistician
Vall d´Hebron Institute of Oncology
Teresa Macarulla
Head of Gastrointestinal and Endocrine Tumor Unit
Hospital Clínic de Barcelona
Paolo Nuciforo
Head
Vall d´Hebron Institut d´Oncologia
Martin Espinosa-Bravo
Head of Breast Surgical Unit
-
Concepción Violán
Seniror Researcher_Family Physisician
Institut Català de la Salut
Manuel Hernandez-Gonzalez
Head of service
Hospital Universitari Vall d'Hebron
Sandra Peiró
Head of the Chromatin Dynamics in Cancer Group
Vall d'Hebron Institute of Oncology
Paula Jimenez-Fonseca
Central University Hospital of Asturias
Manel Esteller
Group Leader, Cancer Epigenetics Group
Josep Carreras Leukaemia Research Institute
Danai Fimereli
Université libre de Bruxelles (ULB)
Trevor J. Pugh
Professor
University Health Network
Cesar Serrano
External Group Leader (TRIP-Clinic program)
IRB Barcelona
Gabriele Zoppoli
University of Genoa
Violeta Serra
Group Leader
Vall d'Hebron Institute of Oncology
Alex Sánchez-Pla
Professor
University of Barcelona
Carlos E de Andrea
-
Gloria Castillo
Vall d'Hebron Institute of Oncology
TIAN TIAN
Vall d'Hebron Institute of Oncology
Make your next move.
Prepare your application
Review drafts before you send them.